Stock analysis · Bull Rankings model

ISRG analysis

Intuitive Surgical, Inc.Medical Instruments & Supplies. Scored on the same transparent model behind the daily rankings.

Robotics & Automation
ISRG
Intuitive Surgical, Inc. · Medical Instruments & Supplies
FCF$3.2bB
Rev+20.7%A-
D/E
P/E43.5xC
PEG1.95C+
73.2Score
$378.81$135.7B
1Y Target$478.01Analyst consensus · 30 analysts
5Y Target$699.85Compound horizon
10Y Target$1,038Long-dated conviction
FCF$3.2bTTM
B
FCF $3.2b — solid, comfortably covers operations and capital return
Rev+20.7%TTM YoY
A-
Revenue +20.7% — strong growth, well above S&P median (~7%)
D/E
D/E data unavailable — neutral default
P/E43.5x
C
P/E 43.5 — expensive vs Healthcare peers (≈90th pctile)
PEG1.95
C+
PEG 1.95 — modest premium; above fair value

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 73.2
Quality83.7
Growth93.2
Value50.3
Entry · Margin of safety
52-week rangeNear 52-week low
37% off the 12-month high
vs DCF fair value222% aboveest. fair value ~$118
What the price assumes: free cash flow compounding at ~40% a year for the next decade — vs the ~12% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability35% · B+gross profit ÷ total assets (Novy-Marx)
ROIC15.0% · A-return on invested capital — not score-weighted

Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.

Why now
The single most compelling reason to own ISRG is the unstoppable expansion of its da Vinci Surgical System, now bolstered by the Ion endoluminal platform, which together lock in hospitals seeking minimally invasive solutions. The business is delivering 20.7% revenue growth YoY, a 28.4% profit margin and generates $3.2 B of free cash flow, all while our Bull Rankings model awards a stellar Growth pillar (99) within a 75.7 overall quality‑growth score. The thesis rests on the ability of these platforms to compound earnings as more procedures shift to robotic and endoluminal techniques.
Moat
ISRG’s moat stems from the integrated da Vinci ecosystem—hardware, proprietary instruments, and a learning pathway that hospitals embed into their surgical suites, creating high switching costs and recurring revenue from consumables. Its ROE of 17.3% reflects pricing power derived from category leadership in robotic surgery, a position competitors cannot replicate quickly without massive R&D and regulatory hurdles.
Risk
The bear case centers on the lofty valuation: a forward P/E of 42.3 implies the market expects growth far above the historical 20.7% rate, and the Bull Rankings model flags Value as the weakest pillar (52), suggesting the price may already be pricing in unrealistic free‑cash‑flow growth of ~39% per year. A slowdown in procedure adoption or a successful competitor entry that erodes margin would push the stock toward its 52‑week low of $328.57, confirming the downside.
Horizon
1-3 yr $478.01 (30-analyst consensus) — fundamentals + valuation re-rating. 5 yr $699.85 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,038 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

ISRG vs the Top Picks average

PillarISRGBook avgDiff
Quality0.840.84in line
Growth0.930.84+0.09
Value0.500.78-0.28

Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.

Trend
+1.6 over 46 daily scores
From 71.6 (Jun 22) → 73.2 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Analyst estimate revisions

30-day change+0.5%
90-day change+2.4%
Forward EPS estimate$12.07

Over the last 90 days, what analysts expect ISRG to earn is drifting higher (+2.4%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.

A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →

Shares to buy
5
Position size
$1,894
3.8% of portfolio
Stop price
$284.11
25% below $378.81
$ at risk if stopped
$473.51
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Intuitive Surgical, Inc. (ISRG): score, valuation & FAQ

Intuitive Surgical, Inc. (ISRG) is a Medical Instruments & Supplies company that scores 73.2 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

Its strongest graded signals are Rev (A-). On valuation, ISRG sits about 222% above our discounted-cash-flow fair value — the current price implies roughly 40% annual free-cash-flow growth over the next decade.

Is ISRG a good stock to buy?

Bull Rankings scores ISRG 73.2 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A-). A score is a quantitative screen of Intuitive Surgical, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does ISRG score 73.2 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ISRG earns its highest marks on Rev (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is ISRG overvalued or undervalued?

Based on $378.81, ISRG sits about 222% above our discounted-cash-flow fair value — the current price implies roughly 40% annual free-cash-flow growth over the next decade. It trades at a 43.5x P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.

What are the main risks of investing in ISRG?

The bear case centers on the lofty valuation: a forward P/E of 42.3 implies the market expects growth far above the historical 20.7% rate, and the Bull Rankings model flags Value as the weakest pillar (52), suggesting the price may already be pricing in unrealistic free‑cash‑flow growth of ~39% per year. A slowdown in procedure adoption or a successful competitor entry that erodes margin would push the stock toward its 52‑week low of $328.57, confirming the downside.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.

More Medical Devices & Diagnostics stocks by score

All Healthcare rankings →

Analyze another ticker →